S&P 500   3,823.86 (-0.46%)
DOW   30,733.04 (-0.85%)
QQQ   325.57 (+0.05%)
AAPL   141.73 (+1.91%)
MSFT   226.02 (+0.03%)
FB   274.79 (+0.11%)
GOOGL   1,886.11 (-0.34%)
AMZN   3,286.47 (-0.17%)
TSLA   865.00 (+2.17%)
NVDA   538.31 (-1.86%)
BABA   261.75 (+1.21%)
CGC   33.04 (-2.25%)
GE   10.87 (-2.16%)
MU   80.10 (-2.65%)
AMD   93.14 (+0.38%)
NIO   60.86 (-1.76%)
T   28.84 (-0.31%)
F   11.07 (-3.91%)
ACB   10.23 (-3.94%)
BA   200.96 (-2.37%)
DIS   170.48 (-1.33%)
NFLX   556.32 (-1.57%)
GILD   66.91 (-0.04%)
S&P 500   3,823.86 (-0.46%)
DOW   30,733.04 (-0.85%)
QQQ   325.57 (+0.05%)
AAPL   141.73 (+1.91%)
MSFT   226.02 (+0.03%)
FB   274.79 (+0.11%)
GOOGL   1,886.11 (-0.34%)
AMZN   3,286.47 (-0.17%)
TSLA   865.00 (+2.17%)
NVDA   538.31 (-1.86%)
BABA   261.75 (+1.21%)
CGC   33.04 (-2.25%)
GE   10.87 (-2.16%)
MU   80.10 (-2.65%)
AMD   93.14 (+0.38%)
NIO   60.86 (-1.76%)
T   28.84 (-0.31%)
F   11.07 (-3.91%)
ACB   10.23 (-3.94%)
BA   200.96 (-2.37%)
DIS   170.48 (-1.33%)
NFLX   556.32 (-1.57%)
GILD   66.91 (-0.04%)
S&P 500   3,823.86 (-0.46%)
DOW   30,733.04 (-0.85%)
QQQ   325.57 (+0.05%)
AAPL   141.73 (+1.91%)
MSFT   226.02 (+0.03%)
FB   274.79 (+0.11%)
GOOGL   1,886.11 (-0.34%)
AMZN   3,286.47 (-0.17%)
TSLA   865.00 (+2.17%)
NVDA   538.31 (-1.86%)
BABA   261.75 (+1.21%)
CGC   33.04 (-2.25%)
GE   10.87 (-2.16%)
MU   80.10 (-2.65%)
AMD   93.14 (+0.38%)
NIO   60.86 (-1.76%)
T   28.84 (-0.31%)
F   11.07 (-3.91%)
ACB   10.23 (-3.94%)
BA   200.96 (-2.37%)
DIS   170.48 (-1.33%)
NFLX   556.32 (-1.57%)
GILD   66.91 (-0.04%)
S&P 500   3,823.86 (-0.46%)
DOW   30,733.04 (-0.85%)
QQQ   325.57 (+0.05%)
AAPL   141.73 (+1.91%)
MSFT   226.02 (+0.03%)
FB   274.79 (+0.11%)
GOOGL   1,886.11 (-0.34%)
AMZN   3,286.47 (-0.17%)
TSLA   865.00 (+2.17%)
NVDA   538.31 (-1.86%)
BABA   261.75 (+1.21%)
CGC   33.04 (-2.25%)
GE   10.87 (-2.16%)
MU   80.10 (-2.65%)
AMD   93.14 (+0.38%)
NIO   60.86 (-1.76%)
T   28.84 (-0.31%)
F   11.07 (-3.91%)
ACB   10.23 (-3.94%)
BA   200.96 (-2.37%)
DIS   170.48 (-1.33%)
NFLX   556.32 (-1.57%)
GILD   66.91 (-0.04%)
Log in
OTCMKTS:CRXM

Gene Biotherapeutics Stock Forecast, Price & News

$0.04
0.00 (-2.78 %)
(As of 01/22/2021 08:28 PM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04▼
$0.04
50-Day Range
$0.03
MA: $0.04▼
$0.04
52-Week Range
$0.02
Now: $0.04▼
$0.18
Volume237,100 shs
Average Volume478,750 shs
Market Capitalization$507,150.00
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Gene Biotherapeutics, Inc. manages a portfolio of medical technologies in the United States. It focuses on acquiring and developing gene-based therapeutics. The company, through its subsidiary, Angionetics, Inc., focuses on the clinical advancement and commercialization of Generx, an interventional cardiology, angiogenic gene therapy Phase 3 product candidate designed for the potential treatment of patients with refractory angina due to advanced coronary artery disease. It also holds royalties on the commercialization of Excellagen technology platform for advanced wound care in Eurasian countries. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was founded in 2003 and is headquartered in San Diego, California.

MarketRank™

Overall MarketRank™

0.65 out of 5 stars

Medical Sector

1242nd out of 1,923 stocks

Biological Products, Except Diagnostic Industry

148th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CRXM
Previous SymbolNYSE:CXM
CUSIPN/A
CIK772320
Webwww.cardiumthx.com
Phone858-436-1000
Employees6
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares14,490,000
Market Cap$507,150.00
Next Earnings DateN/A
OptionableNot Optionable
$0.04
0.00 (-2.78 %)
(As of 01/22/2021 08:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CRXM News and Ratings via Email

Sign-up to receive the latest news and ratings for CRXM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gene Biotherapeutics (OTCMKTS:CRXM) Frequently Asked Questions

How has Gene Biotherapeutics' stock been impacted by Coronavirus?

Gene Biotherapeutics' stock was trading at $0.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CRXM shares have decreased by 78.1% and is now trading at $0.0350.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Gene Biotherapeutics?

Wall Street analysts have given Gene Biotherapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gene Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Gene Biotherapeutics?

Gene Biotherapeutics saw a increase in short interest in the month of December. As of December 31st, there was short interest totaling 45,500 shares, an increase of 135.8% from the December 15th total of 19,300 shares. Based on an average daily volume of 630,300 shares, the short-interest ratio is currently 0.1 days.
View Gene Biotherapeutics' Short Interest.

Who are some of Gene Biotherapeutics' key competitors?

Some companies that are related to Gene Biotherapeutics include AVAX Technologies (AVXT), Cornwall Resources (CORC), Mymetics (MYMX), Neurobiological Technologies (NTII), Omni Bio Pharmaceutical (OMBP), Panacos Pharmaceuticals (PANC), Protide Pharmaceuticals (PPMD), Tengion (TNGNQ) and VIA Pharmaceuticals (VIAP).
View all of CRXM's competitors.

What other stocks do shareholders of Gene Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Isoray (ISR), Protalix BioTherapeutics (PLX), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Intellipharmaceutics International (IPCIF), MGT Capital Investments (MGTI) and Nokia (NOK).

Who are Gene Biotherapeutics' key executives?

Gene Biotherapeutics' management team includes the following people:
  • Mr. Christopher J. Reinhard, Co-Founder, CEO, Pres, Treasurer, Sec. & Director (Age 67, Pay $164.31k)
  • Mr. Duane Linstrom, Gen. Counsel
  • Mr. James L. Grainer, Chairman, CFO & Sec. (Age 66)
  • Dr. Lois A. Chandler, Chief Operating Officer
  • Dr. Ronald J. Shebuski, Chief Scientific Officer
  • Mr. Kelly D. Scott, VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc (Age 65)

What is Gene Biotherapeutics' stock symbol?

Gene Biotherapeutics trades on the OTCMKTS under the ticker symbol "CRXM."

How do I buy shares of Gene Biotherapeutics?

Shares of CRXM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Gene Biotherapeutics' stock price today?

One share of CRXM stock can currently be purchased for approximately $0.04.

How big of a company is Gene Biotherapeutics?

Gene Biotherapeutics has a market capitalization of $507,150.00. Gene Biotherapeutics employs 6 workers across the globe.

What is Gene Biotherapeutics' official website?

The official website for Gene Biotherapeutics is www.cardiumthx.com.

How can I contact Gene Biotherapeutics?

Gene Biotherapeutics' mailing address is 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121. The company can be reached via phone at 858-436-1000 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.